Ras Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 9.99 Cr
as on 13-12-2024
- Paid Up Capital ₹ 9.99 Cr
as on 13-12-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.14 M
as on 13-12-2024
- Revenue -98.02%
(FY 2022)
- Profit 1.28%
(FY 2022)
- Ebitda 11.03%
(FY 2022)
- Net Worth -22.02%
(FY 2022)
- Total Assets -11.51%
(FY 2022)
About Ras Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 9.99 Cr and a paid-up capital of Rs 9.99 Cr.
The company has closed loans amounting to ₹5.14 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajan Nagar, Pierra Charbonner, and Anil Agarwal serve as directors at the Company.
- CIN/LLPIN
U33110DL2008PTC378612
- Company No.
070383
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Feb 2008
- Date of AGM
23 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ras Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajan Nagar  | Director | 28-Jun-2016 | Current |
Pierra Charbonner  | Director | 29-Sep-2015 | Current |
| Anil Agarwal | Director | 16-Dec-2021 | Current |
Financial Performance and Corporate Structure Insights of Ras Life Sciences.
Ras Life Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 98.02% decrease. The company also saw a slight improvement in profitability, with a 1.28% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ras Life Sciences?
In 2022, Ras Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Biomerieux India Private LimitedActive 26 years 6 monthsRajan Nagar and Anil Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Department Of Biotechnology Creation Date: 14 Mar 2012 | ₹0.91 M | Satisfied |
Department Of Biotechnology Creation Date: 21 Jun 2011 | ₹1.74 M | Satisfied |
Ikp Knowledge Park Creation Date: 18 Feb 2011 | ₹2.50 M | Satisfied |
How Many Employees Work at Ras Life Sciences?
Ras Life Sciences has a workforce of 11 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ras Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ras Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
